Sernova Corp. Stock Toronto S.E.

Equities

SVA

CA81732W1041

Medical Equipment, Supplies & Distribution

Market Closed - Toronto S.E. 03:51:03 2024-04-18 pm EDT 5-day change 1st Jan Change
0.45 CAD -3.23% Intraday chart for Sernova Corp. -13.46% -35.71%
Sales 2024 * - Sales 2025 * - Capitalization 137M 99.25M
Net income 2024 * -31M -22.54M Net income 2025 * -25M -18.17M EV / Sales 2024 * -
Net cash position 2024 * 23.61M 17.17M Net cash position 2025 * 17.72M 12.88M EV / Sales 2025 * -
P/E ratio 2024 *
-3.83 x
P/E ratio 2025 *
-3.75 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 87.29%
More Fundamentals * Assessed data
Dynamic Chart
Sernova Corp. Provides Positive Clinical and Platform Portfolio Update CI
Sernova Corp. Reports Earnings Results for the First Quarter Ended January 31, 2024 CI
Sernova Corp. Announces CFO Changes CI
Sernova Corp. Reports Earnings Results for the Full Year Ended October 31, 2023 CI
Sernova Receives Orphan Drug and Rare Pediatric Disease Designations for its Hemophilia A Program from FDA MT
Sernova Corp. Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System? at the 2023 IPITA-IXA-CTRMS Joint Congress CI
Sernova Announces Positive Interim Phase 1/2 Clinical Data for the Cell Pouch System for Type 1 Diabetes Trial MT
Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System? for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint Congress CI
Sernova Corp. Announces New Preclinical Data for its Novel Cell Therapy Platform, Cell Pouch System, as Potential Treatment for Post-Operative Hypothyroidism at 2023 American Thyroid Association Annual Meeting CI
Sernova Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023 CI
Sernova Corp. Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Device CI
Sernova Names New CEO, Former CEO Assumes Tech Chief Role MT
Sernova Corp. Announces Executive Changes CI
Sernova Corp. Appoints Cynthia Pussinen as Chief Executive Officer CI
Sernova Corp Appoints Modestus Obochi as Chief Business Officer CI
More news
1 week-13.46%
Current month-16.67%
1 month-25.00%
3 months-19.64%
6 months-38.36%
Current year-35.71%
More quotes
1 week
0.45
Extreme 0.45
0.51
1 month
0.38
Extreme 0.375
0.60
3 years
0.38
Extreme 0.375
2.22
5 years
0.10
Extreme 0.095
2.87
10 years
0.10
Extreme 0.095
2.87
More quotes
Managers TitleAgeSince
Chief Executive Officer - 23-09-04
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 21-06-29
Members of the board TitleAgeSince
Director/Board Member 58 12-04-18
Chief Tech/Sci/R&D Officer - 09-04-27
Director/Board Member - 22-09-29
More insiders
Date Price Change Volume
24-04-18 0.45 -3.23% 42,040
24-04-17 0.465 0.00% 32,500
24-04-16 0.465 -1.06% 53,068
24-04-15 0.47 +1.08% 173,556
24-04-12 0.465 -10.58% 114,307

Delayed Quote Toronto S.E., April 18, 2024 at 03:51 pm EDT

More quotes
Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
0.45 CAD
Average target price
3.025 CAD
Spread / Average Target
+572.22%
Consensus